title: The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models.
abstract: The development of new diagnostic/therapeutic modalities for cancer requires a specific understanding of how tumors differ from normal tissues. Though the key components involved in the selective accumulation of 2-deoxy-D-glucose (2-DG) analogs in tumors are known, the relative importance of each is controversial. For this reason glucose transport protein (GLUT) density, hexokinase/glucose-6-phosphatase (GP) activity, and 2-DG biodistribution were measured together in four tumor models and normal murine tissues. Direct binding studies with 3H-cytochalasin B showed that GLUT density was elevated 20-fold in LX-1 tumors. Immunohistochemically in all tumors, the expression of GLUT-1 was highest in the necrotic/ perinecrotic foci and similar in cells not adjacent to necrotic foci. As the retention of 3H-2-DG was similar in all tumors, these data suggest that the GLUT-1 in perinecrotic tumor cells were not rate limiting for 3H-2-DG uptake. Kidney, liver, and lung had high GP activity and rapid clearance of 3H-2-DG. Sodium orthovanadate (5 mumol), a GP inhibitor, increased the concentration of 3H-2-DG in these tissues, suggesting that GP is a rate-limiting enzyme for 3H-2-DG clearance. All tumor homogenates had low GP activity, and hexokinase activity was not elevated compared to normal tissues. Thus, in the tumors studied, the selective accumulation of 3H-2-DG consistently occurred in the absence of significant GP activity without the marked overexpression of hexokinase or GLUT.
authors.affiliation: Du Pont Merck Pharmaceutical Company, Radiopharmaceutical Division, Billerica, MA 01862, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Nelson
authors.forename: J Q
authors.initials: JQ
authors.lastname: Wang
authors.forename: I
authors.initials: I
authors.lastname: Leav
authors.forename: P D
authors.initials: PD
authors.lastname: Crane
mesh_terms: D000818:Animals; D000963:Antimetabolites / Q000493:pharmacokinetics*; D001943:Breast Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D003847:Deoxyglucose / Q000493:pharmacokinetics*; D005260:Female; D005952:Glucose-6-Phosphatase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006593:Hexokinase / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009004:Monosaccharide Transport Proteins / Q000378:metabolism*; D009336:Necrosis; D009368:Neoplasm Transplantation; D014018:Tissue Distribution; D014183:Transplantation, Heterologous; D014316:Tritium
chemical_list: D000963:Antimetabolites; D009004:Monosaccharide Transport Proteins; D014316:Tritium; D003847:Deoxyglucose; D006593:Hexokinase; D005952:Glucose-6-Phosphatase